Currently regarded as the gold standard treatment for patients with moderate-to-severe psoriasis, anti-TNF strategy is achieved by using either a human p75 TNF-receptor Fc fusion protein (etanercept), a humanized chimeric anti-TNF monoclonal antibody (infliximab), or a fully human monoclonal anti-TNF antibody (adalimumab). Here, TNF is linked to psoriasis.